Proton Pump Inhibitors and Gut Microbiota Interactions

Proton pump inhibitors (PPIs) rank among the most widely prescribed medications globally, primarily indicated for the treatment of gastro-oesophageal reflux disease, peptic ulcer disease and eradication regimens for Helicobacter pylori. By irreversibly inhibiting the gastric H+,K+-ATPase enzyme, they elevate intragastric pH, which while alleviating acid-related symptoms also disrupts a fundamental barrier to microbial translocation. This pharmacologically induced hypochlorydia is now recognised as a key driver of alterations in the gut microbiota across the gastrointestinal tract. Large-scale population studies and interventional cohorts consistently report reduced microbial diversity, an overrepresentation of oral and upper gastrointestinal taxa in faecal samples and shifts in enteric community structure—a phenomenon broadly termed dysbiosis. Such dysbiosis is implicated in an increased risk of enteric infections, notably Clostridioides difficile, and small intestinal bacterial overgrowth, and may adversely affect systemic processes, including immune checkpoint inhibitor efficacy in oncology patients. Mechanistic investigations, incorporating metagenomic and metabolomic profiling, have revealed PPI-dependent rewiring of bacterial metabolic pathways, diminished short-chain fatty acid production and perturbation of bile acid metabolism. Emerging evidence from animal models further underscores age- and dose-dependent effects, linking prolonged exposure to mucosal immune modulation and precancerous lesions in biliary epithelium. Collectively, these findings highlight the complex interplay between acid suppression therapy and microbial ecology, with broad implications for clinical practice and the development of microbiome-targeted interventions.

Research from Nature Portfolio

Recent studies have applied shotgun metagenomic sequencing to large human cohorts, demonstrating that PPI use is associated with striking shifts in taxonomic composition, including depletion of commensal anaerobes and overgrowth of facultative bacteria such as Enterococcus and Streptococcus. Functional profiling reveals downregulated pathways for short-chain fatty acid biosynthesis and enhanced antimicrobial resistance gene carriage. In a rodent model, chronic administration of omeprazole induced progressive dysbiosis mirroring that seen under high-fat dietary conditions, with concomitant alterations in bile acid pools, reduced expression of farnesoid X receptor signalling and early markers of biliary epithelial proliferation. Another long-term study in aged rats confirmed an age-dependent loss of microbial diversity and significant declines in colonic butyrate concentrations following prolonged PPI exposure, providing a plausible mechanism for increased susceptibility to pseudomembranous colitis and other inflammatory sequelae in elderly patients.

Proton Pump Inhibitors and Gut Microbiota Interactions publication trend

The graph below shows the total number of articles in proton pump inhibitors and gut microbiota interactions across all publications each year (not limited to Nature Index journals).

Technical terms

Proton pump inhibitor: A class of drugs that irreversibly blocks the gastric H+,K+-ATPase enzyme to suppress acid secretion in the stomach.

Gut microbiota: The community of microorganisms, including bacteria, archaea, viruses and fungi, residing in the gastrointestinal tract.

Metagenomic sequencing: High-throughput genetic analysis of microbial communities to profile taxonomic composition and functional potential without prior cultivation.

Dysbiosis: An imbalance in the microbial community structure associated with reduced diversity and altered metabolic activity.

Alpha-diversity: A measure of species richness and evenness within a single microbial sample.

Beta-diversity: A comparison of microbial community composition between different samples.

Butyrate: A short-chain fatty acid produced by microbial fermentation of dietary fibre, vital for colonic epithelial health and immune regulation.

References

1. Proton pump inhibitors alter the composition of the gut microbiota. Gut (2015).
2. Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility. Microbiome (2014).
3. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nature Communications (2020).
4. Long-term Proton Pump Inhibitor Administration Caused Physiological and Microbiota Changes in Rats. Scientific Reports (2020).
5. Gut microbiota and butyrate level changes associated with the long-term administration of proton pump inhibitors to old rats. Scientific Reports (2019).
6. Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis. Frontiers in Immunology (2023).
7. Proton pump inhibitor-induced gut dysbiosis and immunomodulation: current knowledge and potential restoration by probiotics. Pharmacological Reports (2023).